SEC Filings

Form Description Filing date View
8-K

Report of unscheduled material events or corporate event

View HTML
S-3/A

Pre-effective amendment to an S-3 filing

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML
DEL AM

Delaying amendment

View HTML
S-3

Simplified registration form

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

View HTML

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline